Cargando…
Impact of macular fluid features on outcomes of anti-vascular endothelial growth factor treatment for type 3 macular neovascularization
We evaluated the impact of macular fluid features on visual and anatomical outcomes in type 3 macular neovascularization (MNV) patients treated with anti-vascular endothelial growth factor (VEGF). We retrospectively enrolled 89 eyes with type 3 MNV with at least 12 months of follow-up. All patients...
Autores principales: | Yoon, Wontae, Yoon, Jihyun, Na, Seung Kwan, Lee, Jihyun, Kim, Jaemin, Kim, Jong Woo, Cho, Han Joo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8655104/ https://www.ncbi.nlm.nih.gov/pubmed/34880302 http://dx.doi.org/10.1038/s41598-021-03053-w |
Ejemplares similares
-
Neovascular age-related macular degeneration in which exudation predominantly occurs as a subretinal fluid during anti-vascular endothelial growth factor treatment
por: Cho, Han Joo, et al.
Publicado: (2022) -
Neovascular age-related macular degeneration without exudative recurrence over 24 months after initial remission
por: Cho, Han Joo, et al.
Publicado: (2022) -
Long-term outcome of intravitreal anti-vascular endothelial growth factor treatment for pachychoroid neovasculopathy
por: Yoon, Jihyun, et al.
Publicado: (2021) -
Author Correction: Long-term outcome of intravitreal anti-vascular endothelial growth factor treatment for pachychoroid neovasculopathy
por: Yoon, Jihyun, et al.
Publicado: (2021) -
Clinical Features of Untreated Type 2 Macular Telangiectasia and Efficacy of Anti-Vascular Endothelial Growth Factor Therapy in Macular Neovascularization
por: Çoban Karataş, Müge, et al.
Publicado: (2022)